Highly active antiretroviral therapy and coronary heart disease: The need for perspective

AIDS

Volumn 15, Issue SUPPL. 5, 2001, Pages

  Egger, M ^a   Junghans, C ^a   Friis Moller N ^a   Lundgren, J D ^a  

^a Canynge Hall ^*  (United Kingdom)

Author keywords

Anti HIV agents; Coronary disease; Hyperlipidaemia; Insulin resistance; Lipodystrophy; Prospective studies

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE; ANTIBIOTIC THERAPY; CIGARETTE SMOKING; COMBINATION CHEMOTHERAPY; CORONARY RISK; DIABETES MELLITUS; DRUG RESEARCH; DYSLIPIDEMIA; GENETIC ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPODYSTROPHY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CORONARY DISEASE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0035666817     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200100005-00023     Document Type: Review

References (69)

1. British HIV association guidelines for the treatment of HIV infected adults with antiretroviral therapy
2. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society - USA panel
3. Adverse effects of antiretroviral therapy
4. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
5. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
6. Mortality by cause for eight regions of the world: Global burden of disease study
7. The WHO MONICA Project. A worldwide monitoring system for cardiovascular diseases: Cardiovascular mortality and risk factors in selected communities
8. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations
9. The pathogenesis of atherosclerosis: A perspective for the 1990s
10. Myth and paradox of coronary risk and the menopause
11. Coronary heart disease epidemiology in the 21st century
12. Factors of risk in development of coronary heart disease - Six year follow-up experience: The Framingham Study
13. Epidemiologic contributions to preventive cardiology and challenges for the twenty-first century
14. High density lipoprotein - Relationship of the plasma levels of this lipoportein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase
15. Coronary artery disease: Raised cholesterol or triglycerides?
16. Do triglycerides provide meaningful information about heart disease risk?
17. Epidemiology as a guide to clinical decisions: The association between triglyceride and coronary heart disease
18. Triglyceride as a risk factor for ischaemic heart disease in British men: Effect of adjusting for measurement error
19. Role of insulin resistance in human disease
20. HIV protease inhibitor-related lipodystrophy syndrome
21. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
22. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
23. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection
24. Efavirenz-associated breast hypertrophy in HIV-infection patients
25. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
26. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy
27. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV cohort study
28. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: A longitudinal study
29. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
30. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
31. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
32. Comparison of p-triglyceride levels among HIV-patients on randomised treatment with ritonavir, indinavir or ritonavir/saquinavir
33. Lipid elevation during non-nucleoside RTI (NNRTI) therapy: A cross-sectional analysis
34. Early development of hyperlipidemia in naive HIV + patients initiating antiretroviral therapy with NNRTI and/or PI
35. The mechanism of insulin resistance caused by HIV protease inhibitor therapy
36. Metabolic effects of indinavir in healthy HIV-seronegative men
37. Insulin resistance in HIV protease inhibitor-associated diabetes
38. Impact of diabetes on coronary artery disease in women and men: A meta-analysis of prospective studies
39. Risk factors for coronary heart disease in men 18 to 39 years of age
40. Serum cholesterol in young men and subsequent cardiovascular disease
41. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity
42. An assessment of clinically useful measures of the consequences of treatment
43. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-based medicine working group
44. Cardiovascular disease risk profiles
45. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
46. Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice
47. Long-term cardiovascular effects of anabolic steroids
48. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
49. Cardiac manifestations of acquired immunodeficiency syndrome
50. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men
51. Les facteurs de risque coronarien. Le paradox français
52. Estimation of CHD risk in a French working population using a modified Framingham model
53. How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts
54. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: Comparison of cohort studies with randomized trials. EuroSIDA, the French hospital database on HIV and the Swiss HIV cohort study groups
55. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV cohort study
56. Myocardial infarction incidence in clinical trials of 4 protease inhibitors
57. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men
58. Prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy: Multicohort analysis of 12850 patients
59. To improve the evidence of medicine
60. Incommunicable knowledge? Interpreting and applying the results of clinical trials and meta-analyses
61. Epidemiological studies of cardiovascular diseases
62. Caerphilly and Speedwell collaborative heart disease studies
63. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
64. An updated coronary risk profile. A statement for health professionals
65. Diabetes mellitus
66. Report of the expert committee on the diagnosis classification of diabetes mellitus
67. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study